BridgeBio Oncology Therapeutics BBOT
NASDAQ BBOT
$2.66 -0.18 (-6.34%)
At close: Oct 23, 2026 · 4:00 PM EDT

BridgeBio Oncology Therapeutics (BBOT) Cost of Revenue (2024)

Updated

BridgeBio Oncology Therapeutics' Cost of Revenue was $66,701 in Q1 2024.

Analysis

BridgeBio Oncology Therapeutics (BBOT) Cost of Revenue (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cost of Rev (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 3.27 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 8.10 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 4.29 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 4.40 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 3.71 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 2.52 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 2.81 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 1.58 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 4.09 Bn
10 BridgeBio Oncology Therapeutics 213.11 Mn -1.16 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 66,701.00
API Access

BridgeBio Oncology Therapeutics Cost of Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cost-of-revenue&ticker=BBOT&period=max&api_key=YOUR_API_KEY